Differential maternal-fetal response to androgenizing luteoma or hyperreactio luteinalis.
Lacl of masculinization in female infants whose virilized mothers have h. luteinalis is in contrast to the common finding of fetal masculinization when maternal virilization occurs with luteoma of pregnancy. From the data at hand, this variation in fetal response cannot be explained by differences in the quantity of androgen production nor by the stage of pregnancy when maternal virilization becomes evident. Steroid analysis from cases of h. luteinalis suggests that the placenta may serve as an androgen barrier by aromatizing steroids before they reach the fetus. Testosterone conversion by the placenta of an anencephalic fetus confirms that conversion to estrogens occurs even without significant fetal adrenal activity. Understanding of the breakdown of this mechanism, with resultant fetal masculinization, will require careful evaluation of the steroid milieu in conditions like luteoma in which fetal masculinization often occurs. Both cystic and solid ovarian hyperplasia are recognized as are complications of pregnancy which require proper identification and conservative management. The significant difference in patients at risk for luteoma and h. luteinalis and the pathological and hormonal differences clearly indicate that these are distinct and separate entities.
D000728:Androgens / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D006965:Hyperplasia; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D010053:Ovary / Q000473:pathology; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D013798:Thecoma / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D014770:Virilism
D000728:Androgens; D006063:Chorionic Gonadotropin